DCT
1:26-cv-00463
Orphalan SA v. Novitium Pharma LLC
Key Events
Complaint
Table of Contents
complaint Intelligence
I. Executive Summary and Procedural Information
- Case Name: Orphalan SA v. Novitium Pharma, LLC
- Parties & Counsel:
- Plaintiff: Orphalan SA (France)
- Defendant: Novitium Pharma, LLC (Delaware)
- Plaintiff's Counsel: McCarter & English, LLP
- Case Identification: 1:26-cv-00463, D. Del., 04/22/2026
- Venue Allegations: Plaintiff alleges venue is proper in the District of Delaware because Defendant is incorporated in Delaware, maintains a registered agent in the district, and transacts business in the state, including an intent to market the accused product there upon approval.
- Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) for a generic version of Plaintiff's CUVRIOR® product constitutes an act of infringement of four patents related to a specific crystalline form of trientine tetrahydrochloride.
- Technical Context: The technology concerns a specific, stable crystalline polymorph (Form B) of trientine tetrahydrochloride, a copper-chelating agent used to treat Wilson's disease, a rare genetic disorder that causes copper to accumulate in the body.
- Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendant's submission of ANDA No. 218493 and its associated Paragraph IV certifications. Defendant notified Plaintiff of its ANDA filing via two notice letters, dated August 17, 2023, and October 15, 2025, asserting that the patents-in-suit are invalid, unenforceable, or will not be infringed. Plaintiff's drug, CUVRIOR®, was granted Orphan Drug Exclusivity through April 28, 2029.
Case Timeline
| Date | Event |
|---|---|
| 2018-05-04 | Earliest Priority Date for '436, '577, '861, and '862 Patents |
| 2021-04-27 | U.S. Patent No. 10,988,436 Issued |
| 2021-07-27 | U.S. Patent No. 11,072,577 Issued |
| 2022-04-28 | FDA Approval for Plaintiff's CUVRIOR® (NDA No. 215760) |
| 2023-08-17 | Defendant's First Notice Letter Sent to Plaintiff |
| 2025-07-15 | U.S. Patent No. 12,358,861 Issued |
| 2025-07-15 | U.S. Patent No. 12,358,862 Issued |
| 2025-10-15 | Defendant's Second Notice Letter Sent to Plaintiff |
| 2026-04-22 | Complaint Filed |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 10,988,436 - Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
- Patent Identification: U.S. Patent No. 10,988,436 ("the '436 patent"), titled "Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use," issued on April 27, 2021.
The Invention Explained
- Problem Addressed: The patent describes that existing salt forms of triethylenetetramine (TETA), such as the dichloride salt, suffer from poor stability at room temperature and are sensitive to humidity, complicating the formulation of a stable oral drug and requiring patients to store tablets under special refrigerated conditions '436 Patent, col. 1:47-65
- The Patented Solution: The invention is a new crystalline form of triethylenetetramine tetrahydrochloride, designated "Form B." This form is produced through carefully controlled manufacturing conditions, particularly by performing crystallization at a low temperature (e.g., about 20°C or below), which results in a polymorph with improved handling properties and stability compared to both the prior dichloride salt and another tetrachloride polymorph, "Form A" '436 Patent, col. 2:13-29 The complaint includes a diagram of the underlying trientine tetrahydrochloride chemical structure Compl. ¶16
- Technical Importance: The creation of a room-temperature stable, orally deliverable form of TETA is significant for improving treatment adherence and quality of life for patients with Wilson's disease, a lifelong condition requiring daily medication '436 Patent, col. 1:53-58
Key Claims at a Glance
- The complaint does not identify specific asserted claims, but alleges infringement of "at least one claim" of the '436 patent Compl. ¶26 Independent claim 1 is representative of the patent's core composition claims.
- Independent Claim 1 of the '436 patent requires:
- A crystalline form of triethylenetetramine tetrahydrochloride Form B;
- Characterized by either a specific X-ray powder diffraction (XRPD) pattern or a specific Raman spectrum; and
- Containing no more than 10 weight % of triethylenetetramine tetrahydrochloride Form A.
- The complaint reserves the right to assert other claims, which may include dependent claims that further narrow the characteristics of the crystalline form or its composition.
U.S. Patent No. 11,072,577 - Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
- Patent Identification: U.S. Patent No. 11,072,577 ("the '577 patent"), titled "Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use," issued on July 27, 2021.
The Invention Explained
- Problem Addressed: As with the '436 patent, the invention addresses the need for a stable and effective oral therapy for Wilson's disease '577 Patent, col. 1:45-65
- The Patented Solution: This patent claims the method of using the stable "Form B" crystalline polymorph of triethylenetetramine tetrachloride to treat or prevent Wilson's disease. The patent leverages the improved stability and handling properties of Form B to enable an effective therapeutic method '577 Patent, claim 1 '577 Patent, col. 2:25-34
- Technical Importance: By patenting the specific method of use, the invention provides a layer of protection beyond the composition itself, covering the therapeutic application of the novel crystalline form.
Key Claims at a Glance
- The complaint alleges infringement of "at least one claim" of the '577 patent Compl. ¶41 Independent claim 1 is a representative method of treatment claim.
- Independent Claim 1 of the '577 patent requires:
- A method of treating or preventing Wilson's disease in a subject;
- By administering an effective amount of the crystalline Form B of triethylenetetramine tetrahydrochloride;
- Wherein the Form B is defined by specific XRPD or Raman characteristics and contains no more than 10 wt % of Form A.
- The complaint reserves the right to assert other claims.
U.S. Patent No. 12,358,861 - Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
- Patent Identification: U.S. Patent No. 12,358,861 ("the '861 patent"), titled "Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use," issued on July 15, 2025 Compl. ¶19
- Technology Synopsis: The patent is directed to the same crystalline Form B of triethylenetetramine tetrachloride and a method of reducing copper levels in patients by administering that form Compl. ¶59 This protects a specific therapeutic outcome of using the drug.
- Asserted Claims: The complaint generally asserts at least one claim, covering both the crystalline form and the method of reducing copper levels Compl. ¶61
- Accused Features: The accused ANDA product is alleged to contain the claimed crystalline Form B with no more than 10 weight % of Form A, and its proposed label allegedly instructs its use in a manner that infringes the method claims Compl. ¶¶61-62
U.S. Patent No. 12,358,862 - Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
- Patent Identification: U.S. Patent No. 12,358,862 ("the '862 patent"), titled "Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use," issued on July 15, 2025 Compl. ¶20
- Technology Synopsis: This patent is directed to the crystalline Form B, pharmaceutical compositions containing it, and methods of treating Wilson's disease Compl. ¶82 A key distinction in the allegations against this patent is a different purity threshold: it claims Form B containing "no more than 50 weight %" of Form A, which is a broader scope than the other asserted patents Compl. ¶84
- Asserted Claims: The complaint generally asserts at least one claim covering the composition and method of treatment Compl. ¶84
- Accused Features: The accused ANDA product is alleged to contain the claimed crystalline Form B and to meet the "no more than 50 weight %" purity threshold for Form A Compl. ¶84 The proposed label allegedly instructs its use for treating Wilson's disease Compl. ¶85
III. The Accused Instrumentality
Product Identification
The accused instrumentality is Novitium Pharma, LLC's proposed generic trientine tetrahydrochloride tablets, 300 mg, which are the subject of ANDA No. 218493 ("Novitium's Proposed ANDA Product") Compl. ¶4
Functionality and Market Context
Novitium's Proposed ANDA Product is intended as a generic equivalent to Orphalan's CUVRIOR® tablets, a copper chelator indicated for the treatment of adult patients with stable Wilson's disease Compl. ¶1 Compl. ¶15 The complaint alleges that the accused product contains, and/or is manufactured using, the specific "crystalline form of trientine tetrahydrochloride Form B" and that its proposed labeling will be "substantially identical" to the CUVRIOR® label, instructing physicians to use it in an infringing manner Compl. ¶26 Compl. ¶39
IV. Analysis of Infringement Allegations
'436 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A crystalline form of triethylenetetramine tetrahydrochloride Form B having at least one of the following characteristics... | On information and belief, Novitium's Proposed ANDA Product contains and/or is manufactured using a crystalline form of trientine tetrahydrochloride Form B. | ¶26 | col. 2:22-29 |
| wherein the crystalline form contains no more than 10 weight % of triethylenetetramine tetrahydrochloride Form A... | ...wherein the crystalline form contains no more than 10 weight % of trientine tetrahydrochloride Form A... | ¶26 | col. 3:20-24 |
'577 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method of treating or preventing Wilson's disease in a subject... | The proposed labeling for the ANDA product is alleged to be substantially identical to the CUVRIOR® label, which is indicated for the treatment of stable Wilson's disease. | ¶39; ¶40 | col. 14:3-4 |
| which method comprises the administration to said subject of an effective amount of a crystalline form of triethylenetetramine tetrahydrochloride Form B... | The ANDA product is alleged to contain the claimed crystalline Form B, and the proposed labeling allegedly instructs and encourages physicians to administer it to patients. | ¶38; ¶39 | col. 2:25-34 |
- Identified Points of Contention:
- Technical Questions: A primary point of contention will be the physical characterization of Novitium's Proposed ANDA Product. The case will likely depend on competing analytical chemistry evidence (e.g., XRPD, Raman spectroscopy) to determine if the active pharmaceutical ingredient in Novitium's product is, in fact, the claimed "Form B" and if it meets the claimed purity limitations with respect to "Form A."
- Scope Questions: The dispute may raise the question of whether the definition of "Form B" is limited to the specific manufacturing process disclosed in the patents (e.g., low-temperature crystallization). Novitium may argue its product, even if spectrally similar, is produced by a different process and thus falls outside the claim scope.
V. Key Claim Terms for Construction
The Term: "crystalline form of triethylenetetramine tetrahydrochloride Form B"
Context and Importance: This term defines the core of the patented invention. The entire infringement analysis for all four patents hinges on whether Novitium's product is properly characterized as this specific polymorph.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The claims define "Form B" primarily by its objective, measurable characteristics, such as having specific peaks in an XRPD pattern or shifts in a Raman spectrum '436 Patent, claim 1 Plaintiff may argue that any crystalline form meeting these spectral definitions is "Form B," regardless of the process used to make it.
- Evidence for a Narrower Interpretation: The specification repeatedly emphasizes that "Form B" is produced by "carefully controlling the conditions of manufacture, in particular the temperature and rate of crystallisation" at or below 20°C '436 Patent, col. 2:22-26 Defendant may argue that "Form B" should be construed as being limited to the product of this specific low-temperature process.
The Term: "contains no more than 10 weight % of triethylenetetramine tetrachloride Form A"
Context and Importance: This negative limitation defines the required purity of the claimed Form B and is an essential element for infringement. Proving that an accused product satisfies this limitation (i.e., is sufficiently pure) is a key part of Plaintiff's burden.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The claims and specification present this as a clear quantitative boundary '436 Patent, claim 1 '436 Patent, col. 3:20-24 Plaintiff will likely argue the plain meaning should apply, and the term requires no special construction.
- Evidence for a Narrower Interpretation: Practitioners may focus on this term because the precision and reliability of methods used to quantify the weight percentage of different polymorphs in a mixture can be a point of expert dispute. Defendant may challenge the validity or applicability of the analytical methods used by Plaintiff to prove the accused product is below the 10% threshold, thereby questioning whether infringement can be definitively established.
VI. Other Allegations
- Indirect Infringement: The complaint alleges that Novitium will induce infringement of the method claims in the '577, '861, and '862 patents. The basis for this allegation is that Novitium's proposed product label will be "substantially identical" to the CUVRIOR® label, which allegedly "instructs and encourages physicians to practice the claimed methods" Compl. ¶39 Compl. ¶62 Compl. ¶85
- Willful Infringement: The complaint does not use the term "willful," but it alleges that Novitium has "actual knowledge" of the patents-in-suit, as demonstrated by its notice letters that reference the patents and their listing in the FDA's Orange Book Compl. ¶27 Compl. ¶42 Compl. ¶65 Compl. ¶88 These allegations could form the basis for a claim for enhanced damages under 35 U.S.C. § 284. The complaint also seeks a declaration that the case is "exceptional" under 35 U.S.C. § 285, which is the standard for an award of attorney's fees Compl., Prayer for Relief ¶G
VII. Analyst's Conclusion: Key Questions for the Case
- A central evidentiary question will be one of polymorphic characterization: Can Plaintiff prove, through analytical techniques like X-ray diffraction and Raman spectroscopy, that the active ingredient in Novitium's proposed generic product is the specific crystalline "Form B" and meets the purity levels required by the asserted claims?
- A key legal question will be one of claim scope: Is the definition of "Form B" limited to the product of the specific low-temperature crystallization process described in the patents, or does it more broadly cover any substance exhibiting the claimed spectral characteristics, irrespective of how it was made?
- A significant issue for the method patents will be induced infringement: Assuming the accused product contains the claimed crystalline form, will Novitium's proposed product label, by virtue of its similarity to the CUVRIOR® label, be found to demonstrate the specific intent required to encourage or instruct infringement by medical professionals?
Analysis metadata
Loading Complaint
Suggested improvements